This 1 Company May Still Be the Best Contrarian Play of the Year

Here’s why Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may still be one of the best contrarian plays for 2017.

| More on:

In October of last year, I wrote about why I thought Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be the best contrarian play for 2017; since then, a lot has happened.

I thought I would revisit the Valeant turnaround thesis once more, this time with the emphasis on the pharmaceutical company’s management team — a management team I believe has done an amazing job of creating value for shareholders over the course of the past six to 12 months.

Investors want to know what they are going to get

Uncertainty is a terrible thing in general; I want to know what is for dinner, how long I will have to wait in line for that new movie everyone wants to see, and, overall, what my rate of return will be on a given investment.

With Valeant, trying to gauge what my return on investment will be this year or next year may be extremely difficult; however, what has become clear in management’s execution of its strategic plan is that I will be able to gauge with some certainty where the company is going and how the company intends to get there.

The ability of any management team to do what they say they are going to do should not be undervalued. In my opinion, part of the recent (deserved) rise in the value of Valeant stock can be attributed to investors simply giving the company’s management props for getting the business to where it is today in terms of debt reduction and a return to a reasonable path to long-term profitability.

Divestitures can support a return to organic growth

The company’s latest divestiture of its iNova Pharmaceuticals business for nearly $1 billion in cash is yet another in a long list of steps the company has made to move toward its goal of paying down $5 billion of debt by early 2018. Valeant remains a significant player in terms of its drug portfolio, and while its R&D program isn’t what it once was (due to a shift toward an infamous and ineffective buy-and-hike acquisition program), the company has a decent pipeline of drugs as well a number of valuable pieces it can still sell off to focus on returning to its “organic” growth roots.

Following a divestiture plan strictly can be a difficult thing to do (obviously, the company’s best drugs will be the first ones potential suitors call about); however, at this point in time, with the company’s stock price hit so hard of late, raising capital via an equity issuance just doesn’t make as much sense as biting the bullet and repaying debt as quickly as possible.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »

engineer at wind farm
Energy Stocks

Invest $20,000 in This Dividend Stock for $100 in Monthly Passive Income

This dividend stock has it all – a strong outlook, monthly income, and even more to consider buying today.

Read more »

Hourglass and stock price chart
Stock Market

It’s Not Too Late: Invest in These TSX Growth Stocks Now

Solid fundamentals of these top TSX growth stocks could help them maintain strong upward momentum in the years to come.

Read more »

coins jump into piggy bank
Dividend Stocks

The Smartest Dividend Stocks to Buy With $500 Right Now

These top dividend stocks both offer attractive yields and trade off their highs, making them two of the best to…

Read more »

stocks climbing green bull market
Stocks for Beginners

3 TSX Stocks Soaring Higher With No Signs of Slowing

Don't ignore stocks just because they look like they're at a high price. Instead, see exactly why they've driven so…

Read more »

dividends can compound over time
Bank Stocks

Is TD Bank Stock a Buy for Its 5.2% Dividend Yield?

TD Bank stock offers a rare 5.2% dividend yield—can it rebound from challenges and reward contrarian investors? Here's what to…

Read more »

chart reflected in eyeglass lenses
Investing

How Should a Beginner Invest in Stocks? Start With This Index Fund

This Vanguard index fund is the perfect way to start a Canadian investment portfolio.

Read more »

analyze data
Bank Stocks

Is BMO Stock a Buy for its 4.7% Dividend Yield?

Bank of Montreal is up 20% since late August. Are more gains on the way?

Read more »